[{"id":"7bf4c100-c992-4e7a-9ed8-b32c4d26ea43","acronym":"SWOG 1512","url":"https://clinicaltrials.gov/study/NCT02775851","created_at":"2021-01-18T13:36:44.518Z","updated_at":"2025-02-25T12:26:29.443Z","phase":"Phase 2","brief_title":"Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02775851 - SWOG 1512","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 02/06/2017","start_date":" 02/06/2017","primary_txt":" Primary completion: 04/14/2023","primary_completion_date":" 04/14/2023","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2025-02-24"},{"id":"8c8f22b1-e6b8-42e7-9888-20229cd33cd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04706663","created_at":"2021-01-19T20:51:39.257Z","updated_at":"2025-02-25T12:27:52.510Z","phase":"","brief_title":"Precision-Based Genomics in Prostate Cancer","source_id_and_acronym":"NCT04706663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM","pipe":" | ","alterations":" TMB-H","tags":["TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"},{"id":"722e7e39-2b2e-4e81-be40-58b1e321be96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043713","created_at":"2023-09-21T15:10:30.740Z","updated_at":"2025-02-25T13:41:44.027Z","phase":"Phase 1","brief_title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations","source_id_and_acronym":"NCT06043713","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 02/09/2026","study_completion_date":" 02/09/2026","last_update_posted":"2025-02-21"},{"id":"8100f49e-ecbc-41b2-9130-5ed625da8fc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669496","created_at":"2025-02-25T13:40:17.235Z","updated_at":"2025-02-25T13:40:17.235Z","phase":"Phase 2/3","brief_title":"Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors","source_id_and_acronym":"NCT04669496","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" TMB • MSI • CEACAM5 • MUC16","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • MSI • CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"913a7f90-f43b-43fc-9a5c-45399bce2739","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907475","created_at":"2021-01-18T19:14:04.518Z","updated_at":"2025-02-25T13:39:50.577Z","phase":"Phase 2","brief_title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)","source_id_and_acronym":"NCT03907475","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD4 • IL2","pipe":"","alterations":" ","tags":["TMB • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"4cc7d5ae-d434-4c5a-bf92-880e3c64f923","acronym":"NCI-2016-01130","url":"https://clinicaltrials.gov/study/NCT02849496","created_at":"2021-01-18T13:59:18.008Z","updated_at":"2025-02-25T13:52:10.914Z","phase":"Phase 2","brief_title":"Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer","source_id_and_acronym":"NCT02849496 - NCI-2016-01130","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TMB • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 positive • BRCA mutation","tags":["HER-2 • TMB • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Tecentriq (atezolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/30/2017","start_date":" 03/30/2017","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-20"},{"id":"9ae6d61c-52ac-447d-9656-ee355853d0dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04068194","created_at":"2023-11-15T17:14:49.418Z","updated_at":"2025-02-25T13:52:57.960Z","phase":"Phase 1/2","brief_title":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","source_id_and_acronym":"NCT04068194","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"d2ed8472-39c8-4af1-9dad-9208fa013488","acronym":"MK-3475-016","url":"https://clinicaltrials.gov/study/NCT04098068","created_at":"2023-05-19T16:04:53.467Z","updated_at":"2025-02-25T13:52:58.973Z","phase":"Phase 2","brief_title":"Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)","source_id_and_acronym":"NCT04098068 - MK-3475-016","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/25/2018","start_date":" 01/25/2018","primary_txt":" Primary completion: 05/15/2022","primary_completion_date":" 05/15/2022","study_txt":" Completion: 02/05/2025","study_completion_date":" 02/05/2025","last_update_posted":"2025-02-20"},{"id":"102a276a-2e7a-4a7f-a75b-c71813873058","acronym":"JS001-027-III-HCC","url":"https://clinicaltrials.gov/study/NCT04523493","created_at":"2021-01-18T21:40:02.000Z","updated_at":"2025-02-25T14:02:00.920Z","phase":"Phase 3","brief_title":"Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC","source_id_and_acronym":"NCT04523493 - JS001-027-III-HCC","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 530","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-19"},{"id":"e34a5a55-d8a1-4469-8532-07c6096c4f21","acronym":"KELLY","url":"https://clinicaltrials.gov/study/NCT03222856","created_at":"2021-01-18T15:54:23.632Z","updated_at":"2025-02-25T14:01:19.405Z","phase":"Phase 2","brief_title":"Ph II Study of Pembrolizumab \u0026 Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines \u0026 Taxanes","source_id_and_acronym":"NCT03222856 - KELLY","lead_sponsor":"MedSIR","biomarkers":" HER-2 • PD-L1 • ER • PGR • TMB","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 12/23/2020","study_completion_date":" 12/23/2020","last_update_posted":"2025-02-19"},{"id":"03ad2ae1-62eb-4ee9-9973-fa23d5f2634d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904496","created_at":"2023-06-15T17:08:23.801Z","updated_at":"2025-02-25T14:18:02.487Z","phase":"Phase 1","brief_title":"A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05904496","lead_sponsor":"BeiGene","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-30813"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-17"},{"id":"3ca1aa84-454a-4672-b1ec-5f4822932e1e","acronym":"CONNECT","url":"https://clinicaltrials.gov/study/NCT05701150","created_at":"2023-01-27T17:59:52.848Z","updated_at":"2025-02-25T14:17:33.658Z","phase":"","brief_title":"AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT","source_id_and_acronym":"NCT05701150 - CONNECT","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"],"overall_status":"Recruiting","enrollment":" Enrollment 3000","initiation":"Initiation: 12/08/2022","start_date":" 12/08/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-17"},{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"b24e71ea-fdd0-4abb-be7e-df7c10fbc959","acronym":"BEGIN","url":"https://clinicaltrials.gov/study/NCT06272864","created_at":"2024-02-22T17:27:27.414Z","updated_at":"2025-02-25T14:10:41.690Z","phase":"","brief_title":"BostonGene and Exigent Genomic INsight Study","source_id_and_acronym":"NCT06272864 - BEGIN","lead_sponsor":"BostonGene","biomarkers":" TMB • MSI","pipe":"","alterations":" ","tags":["TMB • MSI"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 04/08/2024","start_date":" 04/08/2024","primary_txt":" Primary completion: 01/08/2026","primary_completion_date":" 01/08/2026","study_txt":" Completion: 01/08/2028","study_completion_date":" 01/08/2028","last_update_posted":"2025-02-17"},{"id":"77b5e130-b913-4feb-83da-546aed463f8e","acronym":"TELMA","url":"https://clinicaltrials.gov/study/NCT03836066","created_at":"2021-01-18T18:56:22.313Z","updated_at":"2025-02-25T15:11:03.613Z","phase":"Phase 2","brief_title":"Atezolizumab Plus Bevacizumab in First Line NSCLC Patients","source_id_and_acronym":"NCT03836066 - TELMA","lead_sponsor":"Fundación GECP","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 05/15/2019","start_date":" 05/15/2019","primary_txt":" Primary completion: 10/21/2024","primary_completion_date":" 10/21/2024","study_txt":" Completion: 10/21/2024","study_completion_date":" 10/21/2024","last_update_posted":"2025-02-13"},{"id":"c6ceadea-5216-44bc-b521-a84f4461c694","acronym":"","url":"https://clinicaltrials.gov/study/NCT03389802","created_at":"2021-01-18T16:43:48.401Z","updated_at":"2025-02-25T15:10:43.667Z","phase":"Phase 1","brief_title":"Phase I Study of APX005M in Pediatric Central Nervous System Tumors","source_id_and_acronym":"NCT03389802","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" TMB • TNFA • CXCL8 • CD4","pipe":"","alterations":" ","tags":["TMB • TNFA • CXCL8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sotigalimab (PYX-107)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-13"},{"id":"6d9c9dc1-5735-46b5-bfc4-9aa69eeeef0c","acronym":"BFAST","url":"https://clinicaltrials.gov/study/NCT03178552","created_at":"2021-01-18T15:40:25.224Z","updated_at":"2025-02-25T15:17:28.532Z","phase":"Phase 2/3","brief_title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03178552 - BFAST","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF • TMB","pipe":"","alterations":" ","tags":["BRAF • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • gemcitabine • Rozlytrek (entrectinib) • docetaxel • Alecensa (alectinib) • Cotellic (cobimetinib) • pemetrexed • divarasib (RG6330)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 09/22/2017","start_date":" 09/22/2017","primary_txt":" Primary completion: 08/03/2028","primary_completion_date":" 08/03/2028","study_txt":" Completion: 08/03/2028","study_completion_date":" 08/03/2028","last_update_posted":"2025-02-12"},{"id":"b172bb8d-07dd-4d40-b459-cb7946457b73","acronym":"NRG-BN007","url":"https://clinicaltrials.gov/study/NCT04396860","created_at":"2021-01-18T21:13:04.295Z","updated_at":"2025-02-25T15:34:40.901Z","phase":"Phase 2/3","brief_title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","source_id_and_acronym":"NCT04396860 - NRG-BN007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • IDH1 • MGMT","pipe":" | ","alterations":" PD-L1 expression • MGMT promoter methylation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MGMT promoter methylation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 04/13/2023","primary_completion_date":" 04/13/2023","study_txt":" Completion: 03/11/2025","study_completion_date":" 03/11/2025","last_update_posted":"2025-02-10"},{"id":"ef70bd40-bf79-48c4-9e4c-bf5799b604fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04605731","created_at":"2021-01-19T20:31:23.461Z","updated_at":"2025-02-25T16:45:12.247Z","phase":"Phase 1","brief_title":"Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer","source_id_and_acronym":"NCT04605731","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • SIR-Spheres (yttrium-90 microspheres)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/03/2021","start_date":" 08/03/2021","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 08/25/2025","study_completion_date":" 08/25/2025","last_update_posted":"2025-02-06"},{"id":"a72076f2-45ad-4489-9265-7203d8923c89","acronym":"cRISK","url":"https://clinicaltrials.gov/study/NCT06792721","created_at":"2025-02-25T16:49:00.895Z","updated_at":"2025-02-25T16:49:00.895Z","phase":"","brief_title":"MEASUREMENT of CIRCULATING MUTATION BURDEN","source_id_and_acronym":"NCT06792721 - cRISK","lead_sponsor":"Centre Francois Baclesse","biomarkers":" TMB • BRCA","pipe":"","alterations":" ","tags":["TMB • BRCA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/15/2025","start_date":" 02/15/2025","primary_txt":" Primary completion: 02/15/2027","primary_completion_date":" 02/15/2027","study_txt":" Completion: 08/30/2027","study_completion_date":" 08/30/2027","last_update_posted":"2025-02-05"},{"id":"5ba9d628-6d23-4d5d-9027-4c4a55c8330e","acronym":"NCI-2019-08626","url":"https://clinicaltrials.gov/study/NCT04214249","created_at":"2024-01-11T17:17:48.143Z","updated_at":"2025-02-25T17:00:21.915Z","phase":"Phase 2","brief_title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04214249 - NCI-2019-08626","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 11/27/2024","primary_completion_date":" 11/27/2024","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-03"},{"id":"67575df3-fe79-49cd-97ab-2aa59bfde6c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02359565","created_at":"2021-01-18T11:13:52.172Z","updated_at":"2025-02-25T16:58:45.335Z","phase":"Phase 1","brief_title":"Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma","source_id_and_acronym":"NCT02359565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" TMB-H","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 12/21/2025","primary_completion_date":" 12/21/2025","study_txt":" Completion: 12/21/2025","study_completion_date":" 12/21/2025","last_update_posted":"2025-02-03"},{"id":"7460cc37-d435-44b0-a888-a97d57a2e6c3","acronym":"START-001","url":"https://clinicaltrials.gov/study/NCT05592626","created_at":"2022-10-24T13:57:11.728Z","updated_at":"2025-02-25T17:31:39.938Z","phase":"Phase 1/2","brief_title":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05592626 - START-001","lead_sponsor":"Marengo Therapeutics, Inc.","biomarkers":" KRAS • TMB • MSI • RAS","pipe":" | ","alterations":" KRAS mutation • TMB-H • MSI-H/dMMR • RAS mutation • RAS wild-type","tags":["KRAS • TMB • MSI • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • MSI-H/dMMR • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e invikafusp alfa (STAR0602)"],"overall_status":"Recruiting","enrollment":" Enrollment 365","initiation":"Initiation: 01/04/2023","start_date":" 01/04/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-01-30"}]